Shire Integration Prep Progresses As Takeda Logs Solid 1Q
Takeda and Shire are already discussing their planned integration across multiple areas, but until the deal closes formally the Japanese firm stresses it is business as usual, as it reports solid underlying growth in the fiscal first quarter, driven by core products.
You may also be interested in...
Takeda is facing major revenue challenges from US generics to its big seller Velcade, but is looking to successor and other new products to more than plug the gap.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.